Immunic, Inc
Immunic, Inc. is a late-stage biotechnology company developing oral small-molecule therapies for chronic inflammatory, autoimmune, neurologic, and gastrointestinal diseases. Its lead program, vidofludimus calcium (IMU-838), is in Phase 3 development for relapsing multiple sclerosis, while IMU-856 and IMU-381 target gastrointestinal and autoimmune indications.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2021–2025
Liiketoiminta
Osuus liikevaihdostaPhase 3 oral therapy for relapsing multiple sclerosis with prior activity in MS and ulcerative colitis studies.
Oral program aimed at regenerating bowel epithelium and restoring intestinal barrier function.
Next-generation molecules leveraging the Nurr1 platform for GI and autoimmune diseases.
Internal research, translational work, and clinical development infrastructure supporting the pipeline.
Asiakkaat
Immunic does not sell commercial products today; its “customers” are primarily patients, physicians, and regulators that determine whether its drug candidates can advance and eventually be approved. The company also depends on clinical trial sites, contract research organizations, and development partners to execute studies across its target indications.
Patients with relapsing multiple sclerosis and related neurologic disease who are the target population for IMU-838.
Patients with ulcerative colitis, celiac disease, IBD, and GvHD targeted by IMU-856 and IMU-381.
Neurologists, gastroenterologists, and key opinion leaders who assess clinical data and influence future adoption.
FDA, EMA, and reimbursement stakeholders that determine approval, labeling, and market access.
CROs, investigators, and trial sites that buy services from the company indirectly through study execution.
Strategia
Immunic’s strategy is to advance its oral immunology pipeline through late-stage clinical proof-of-concept, with IMU-838 as the lead value driver. The company is also broadening optionality by developing IMU-856 and IMU-381 for adjacent gastrointestinal and autoimmune indications, while preserving capital through a focused development model.
Phase 3 success is the main path to regulatory approval and future commercialization.
IMU-856 and IMU-381 diversify the company beyond a single lead asset and broaden addressable markets.
As a clinical-stage company with no product revenue, financing discipline is essential to keep programs moving.
Maantiede
Immunic is headquartered in New York City, but its main operations are in Gräfelfing near Munich, Germany, making it operationally transatlantic. The company’s clinical development footprint is tied to major markets for MS and gastrointestinal disease, and its foreign operations expose it to euro-denominated costs and currency translation effects.
Riskit
Immunic is a clinical-stage biotech with no product sales, so its value depends on successful trial outcomes, regulatory approvals, and access to capital. The company also faces execution risk from complex, multi-site clinical programs, foreign-currency exposure from its German operations, and the possibility that its candidates may not achieve market acceptance even if approved.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Korkea
The company’s lead assets are still in development, so negative trial data could eliminate or delay commercialization opportunities.
Kohdistuu - Financing and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea
The company has no product sales and will require substantial additional capital to fund trials and operations.
Kohdistuu - Regulatory and market acceptance riskVaikutus: KorkeaTodennäköisyys: Korkea
Even successful trials may not translate into approval, reimbursement, or physician adoption.
Kohdistuu: MS and GI indications
- Operational and trial execution riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Multi-country clinical programs depend on CROs, sites, enrollment, and supply continuity.
Kohdistuu: Clinical operations in the U.S. and Europe
- Foreign exchange riskVaikutus: Keskitaso
German operations use the euro, creating translation and transaction exposure versus U.S. reporting currency.
Kohdistuu: Germany
Kirjanpito
Harkinnanvaraiset erätClinical-stage spending is expensed as incurred, so trial timing directly affects quarterly losses.
Vaikutus: Affects operating loss and cash burn
The Daiichi Sankyo IMU-856 license includes future development, regulatory, sales milestones and royalties.
Vaikutus: Potential future liabilities and expense recognition
Lease liabilities and right-of-use assets reflect office and operational commitments in Germany and the U.S.
Vaikutus: Affects balance sheet leverage and fixed obligations
German operations are euro-functional, so exchange rates affect consolidated results and equity.
Vaikutus: Translation gains/losses in other comprehensive income
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Immunome Inc.
IMNM · Pharmaceutical Preparations
Equillium, Inc.
EQ · Pharmaceutical Preparations
Immatics N.V.
IMTX · Biological Products, (No Diagnostic Substances)
Imunon, Inc.
IMNN · Pharmaceutical Preparations
Ventyx Biosciences, Inc.
Pharmaceutical Preparations
Actinium Pharmaceuticals, Inc.
ATNM · Pharmaceutical Preparations
Päivitetty: 24.9.2026